Core Viewpoint - WuXi Biologics (02269) experienced a 2.08% decline in stock price, trading at HKD 32.9 per share with a transaction volume of HKD 2.72 billion as of July 30 [1] Company Overview - WuXi Biologics is a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - The company held a 48% market share in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Financial Performance - As of the 2024 annual report, WuXi Biologics reported total revenue of HKD 18.675 billion and a net profit of HKD 3.356 billion [1] Analyst Ratings - On July 29, Zhongtai International Securities upgraded the rating to "Buy" and raised the target price to HKD 37.2 [1] Upcoming Events - WuXi Biologics is scheduled to disclose its interim report for the fiscal year 2025 on August 19 [1]
药明生物(02269)下跌2.08%，报32.9元/股